| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
Form 4: Zohar Daphne, Director
Gave 100,000 shares as a gift |
| 04 Nov 2026 |
Form 4: Torres Denice, Director
Bought 5,000 shares ($99.3K) |
| 02 Nov 2026 | 10-Q |
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
Announced positive topline data from Phase 1 driving simulation trial of GlyphAlloTM, showing that GlyphAllo did not impair next-morning driving performance compared to placebo |
| 14 Aug 2026 | SCHEDULE 13G |
| 05 Aug 2026 | SCHEDULE 13G |
| 05 Aug 2026 | SCHEDULE 13G |
| 03 Aug 2026 | 10-Q |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition
Enrollment in Phase 2b BUOY-1 trial of GlyphAlloTM in major depressive disorder (MDD) is on track with topline data expected in 1H 2027 |
| 24 Jun 2026 |
Form 4: Hombach Robert J., Director
Bought 13,000 shares ($236K) |
| 08 Jun 2026 | 10-Q |
| 08 Jun 2026 |
8-K: Results of Operations and Financial Condition
New data from Phase 1 trial of GlyphAgoTM build upon previously reported topline data and further demonstrate GlyphAgoTM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or e... |
| 11 May 2026 | SCHEDULE 13D |
| 11 May 2026 | SCHEDULE 13G |
| 06 May 2026 |
Form 3: Gap Coinvestments CDA, L.p., Director and 3 others
Holds 6,101,582 shares of Common Stock, par value $0.0001 per share ("Common Stock") |
| 06 May 2026 |
Form 3: General Atlantic (SP), L.p., Director and 9 others
Holds 6,101,582 shares of Common Stock, par value $0.0001 per share ("Common Stock") |
| 06 May 2026 |
Form 4: PureTech Health plc, 10% owner and 1 other
Received 16,382,534 shares by conversion |
| 06 May 2026 | SCHEDULE 13D |
| 04 May 2026 |
Form 4: Zohar Daphne, Director
Granted 1,758,599 Stock Option (Right to Buy) |
| 04 May 2026 |
Form 4: White Lauren, Chief Financial Officer
Granted 63,680 Stock Option (Right to Buy) · Received 6,702 shares by conversion |
Loading...